APA (7th ed.) Citation

V, P., Z, S., T, R., A, M., C, H., L, H., . . . MS, A. (2026). Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: A real-world cohort study. Scientific reports. https://doi.org/10.1038/s41598-026-50871-x

Chicago Style (17th ed.) Citation

V, Podder, Sarfraz Z, Ranjan T, McCracken A, Hurmiz C, Hodgson L, Maharaj A, Mahtani R, and Ahluwalia MS. "Survival Outcomes with Trastuzumab Deruxtecan in HER2-positive Vs. HER2-low Breast Cancer Patients with Brain Metastases: A Real-world Cohort Study." Scientific Reports 2026. https://doi.org/10.1038/s41598-026-50871-x.

MLA (9th ed.) Citation

V, Podder, et al. "Survival Outcomes with Trastuzumab Deruxtecan in HER2-positive Vs. HER2-low Breast Cancer Patients with Brain Metastases: A Real-world Cohort Study." Scientific Reports, 2026, https://doi.org/10.1038/s41598-026-50871-x.